Under President Trump’s proposed 2018 budget, healthcare manufacturers will pay more than double the costs of current US regulatory review of their products, including drugs and medical devices.

For 2018, the Trump administration has budgeted over $2 billion in fees to be collected by the US Food and Drug Administration from industry, twice as much as in 2017, according to budget documents released on Thursday.

Citing a constrained budget environment, the proposed budget said industries that benefit from the FDA’s approval “can and should pay for their share.”

The budget does not say if the fee increases would be evenly spread or directed in a particular area.

Read more at www.reuters.com